Literature DB >> 14576051

Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP.

Robert McMillan1, Lei Wang, Aaron Tomer, Janet Nichol, Jeanne Pistillo.   

Abstract

Chronic immune thrombocytopenic purpura (ITP) is manifested by autoantibody-induced platelet destruction. Platelet turnover studies suggest that autoantibody may also affect platelet production. To evaluate this, we studied the effect of plasma from adult patients with chronic ITP on in vitro megakaryocyte production. CD34(+) cells, obtained from healthy donors, were cultured in medium containing PEG-rHuMGDF and 10% plasma from either ITP patients or healthy subjects. Cultures containing plasma from 12 of 18 ITP patients showed a significant decrease (26%-95%) in megakaryocyte production when compared with control cultures. Positive ITP plasmas not only reduced the total number of megakaryocytes produced during the culture period but also inhibited megakaryocyte maturation, resulting in fewer 4N, 8N, and 16N cells. The role of antibody in this suppression is supported by 2 factors: (1) immunoglobulin G (IgG) from ITP patients inhibited megakaryocyte production when compared with control IgG; and (2) adsorption of autoantibody, using immobilized antigen, resulted in significantly less inhibition of megakaryocyte production when compared with unadsorbed plasma. These results show that plasma autoantibody from some adult patients with ITP inhibits in vitro megakaryocyte production, suggesting that a similar effect may occur in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576051     DOI: 10.1182/blood-2003-08-2672

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  103 in total

Review 1.  Immune thrombocytopenia: no longer 'idiopathic'.

Authors:  Keith McCrae
Journal:  Cleve Clin J Med       Date:  2011-06       Impact factor: 2.321

Review 2.  Piecing together the humoral and cellular mechanisms of immune thrombocytopenia.

Authors:  Lisa J Toltl; Ishac Nazi; Reza Jafari; Donald M Arnold
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

3.  Immune thrombocytopenia in children and adults: what's the same, what's different?

Authors:  Harald Schulze; Gerhard Gaedicke
Journal:  Haematologica       Date:  2011-12       Impact factor: 9.941

Review 4.  Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters.

Authors:  Lisa J Toltl; Donald M Arnold
Journal:  Br J Haematol       Date:  2010-11-18       Impact factor: 6.998

5.  Eltrombopag: a new treatment option for chronic refractory adult immune thrombocytopenia.

Authors:  Rojin Park
Journal:  Blood Res       Date:  2015-03

6.  Long-term outcomes of laparoscopic versus open splenectomy for immune thrombocytopenia.

Authors:  Kazuhiro Tada; Masayuki Ohta; Kunihiro Saga; Hiroomi Takayama; Teijiro Hirashita; Yuichi Endo; Hiroki Uchida; Yukio Iwashita; Masafumi Inomata
Journal:  Surg Today       Date:  2017-07-19       Impact factor: 2.549

Review 7.  Immune thrombocytopenia and pregnancy.

Authors:  Srividhya Sankaran; Susan E Robinson
Journal:  Obstet Med       Date:  2011-10-25

8.  Severe Case of Autoimmune Thrombocytopenia First Diagnosed in Pregnancy.

Authors:  K Bolten; A Salama; A Thomas; J Eucker; W Henrich
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-12       Impact factor: 2.915

Review 9.  Laparoscopic splenectomy for primary immune thrombocytopenia: Current status and challenges.

Authors:  Dong Zheng; Chen-Song Huang; Shao-Bin Huang; Chao-Xu Zheng
Journal:  World J Gastrointest Endosc       Date:  2016-09-16

Review 10.  Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.

Authors:  Roberto Stasi; Maria L Evangelista; Sergio Amadori
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.